Sana biotechnology highlights preclinical data from hypoimmune and fusogen platforms at the international society for stem cell research (isscr) 2023 annual meeting

Hypoimmune (hip)-modified cd19-directed car t cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression

SANA Ratings Summary

SANA Quant Ranking